Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $15.50.

A number of brokerages recently weighed in on EPRX. Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th. Finally, Cantor Fitzgerald increased their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th.

Eupraxia Pharmaceuticals Stock Down 2.9%

Shares of NASDAQ EPRX opened at $7.94 on Friday. The stock has a market cap of $285.52 million, a PE ratio of -9.13 and a beta of 1.27. The business has a 50-day moving average price of $8.28 and a 200 day moving average price of $6.71. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $9.32.

Institutional Trading of Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vivo Capital LLC purchased a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $7,965,000. Ally Bridge Group NY LLC purchased a new stake in Eupraxia Pharmaceuticals during the 3rd quarter worth $5,398,000. Ikarian Capital LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter worth about $4,606,000. Squadron Capital Management LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $3,775,000. Finally, Velan Capital Investment Management LP acquired a new stake in Eupraxia Pharmaceuticals in the third quarter valued at $2,077,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.